Vaxine Pty, Ltd.
Vaxine is a biotechnology company dedicated to advancing vaccine science with a focus on developing innovative vaccines using cutting-edge technology, including artificial intelligence. The company aims to have a global impact through high-quality science and efficient translation into human products. Vaxine has a history of pioneering achievements, including the first swine flu pandemic vaccine in 2009, the first AI-designed vaccine in 2019, and the first approved recombinant spike protein vaccine in 2021. It is involved in developing vaccines for a wide range of diseases including COVID-19, influenza, RSV, hepatitis B, Japanese encephalitis, malaria, Ebola, tuberculosis, anthrax, HIV, allergies, cancer immunotherapy, shigella, opioid addiction, Alzheimer's disease, Zika virus, and typhoid fever.
Industries
Nr. of Employees
small (1-50)
Vaxine Pty, Ltd.
Department of Endocrinology, Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia
Patents
Compositions and methods for vaccination against respiratory syncytial virus infection
US-11623004-B2
View Details
Compositions and methods for vaccination against respiratory syncytial virus infection
US-11623004-B2
View DetailsProducts
Adjuvanted recombinant protein vaccine candidates (human)
Recombinant protein subunit vaccine candidates formulated with polysaccharide-based adjuvant particles and TLR/CpG adjuvant combinations; progressed through preclinical testing and Phase 1–3 clinical trials with reported immunogenicity.
Polysaccharide-based adjuvant platform
Platform of polysaccharide-derived adjuvant particles and derivative formulations designed for use with multiple vaccine antigens and compatible with combination adjuvants.
Inhaled and intranasal vaccine formulations
Needle‑free inhaled and intranasal vaccine formulations evaluated in preclinical models for respiratory pathogens and intended to induce mucosal immunity and lung-resident memory.
Therapeutic vaccine candidates
Adjuvant-enhanced recombinant vaccine candidates developed for therapeutic indications including chronic viral infection, oncology and addiction; supported by preclinical and early clinical studies.
Multivalent and pathogen-specific recombinant vaccine candidates
Recombinant antigen vaccine approaches against a range of pathogens (e.g., RSV, influenza, flaviviruses, Ebola, tuberculosis and enteric bacterial pathogens), often formulated with polysaccharide-based adjuvants and evaluated in animal models.
Veterinary vaccine adapted from human platform
Veterinary vaccine formulations adapted from human recombinant protein platforms for use in susceptible zoo species, developed for safety across multiple animal species and deployed in coordination with veterinary authorities.
Adjuvanted recombinant protein vaccine candidates (human)
Recombinant protein subunit vaccine candidates formulated with polysaccharide-based adjuvant particles and TLR/CpG adjuvant combinations; progressed through preclinical testing and Phase 1–3 clinical trials with reported immunogenicity.
Polysaccharide-based adjuvant platform
Platform of polysaccharide-derived adjuvant particles and derivative formulations designed for use with multiple vaccine antigens and compatible with combination adjuvants.
Inhaled and intranasal vaccine formulations
Needle‑free inhaled and intranasal vaccine formulations evaluated in preclinical models for respiratory pathogens and intended to induce mucosal immunity and lung-resident memory.
Therapeutic vaccine candidates
Adjuvant-enhanced recombinant vaccine candidates developed for therapeutic indications including chronic viral infection, oncology and addiction; supported by preclinical and early clinical studies.
Multivalent and pathogen-specific recombinant vaccine candidates
Recombinant antigen vaccine approaches against a range of pathogens (e.g., RSV, influenza, flaviviruses, Ebola, tuberculosis and enteric bacterial pathogens), often formulated with polysaccharide-based adjuvants and evaluated in animal models.
Veterinary vaccine adapted from human platform
Veterinary vaccine formulations adapted from human recombinant protein platforms for use in susceptible zoo species, developed for safety across multiple animal species and deployed in coordination with veterinary authorities.
Services
Joint research collaborations with academic and industry partners to develop vaccine candidates and adjuvant formulations.
Formulation and optimisation of polysaccharide-derived adjuvant particles and combination adjuvants to enhance vaccine immunogenicity and enable dose sparing.
Conduct of immunogenicity, protection and pathogen challenge studies in small animals and nonhuman primates to evaluate candidate efficacy and variant breadth.
Protocol development, trial execution support and data generation for randomized clinical trials including safety, immunogenicity, pediatric and booster studies.
Coordination with third‑party manufacturers for scale-up, fill–finish and distribution support for vaccine and adjuvant products.
Assistance in preparing regulatory dossiers, engaging with national regulators and pursuing provisional determinations and market authorisations.
Joint research collaborations with academic and industry partners to develop vaccine candidates and adjuvant formulations.
Formulation and optimisation of polysaccharide-derived adjuvant particles and combination adjuvants to enhance vaccine immunogenicity and enable dose sparing.
Conduct of immunogenicity, protection and pathogen challenge studies in small animals and nonhuman primates to evaluate candidate efficacy and variant breadth.
Protocol development, trial execution support and data generation for randomized clinical trials including safety, immunogenicity, pediatric and booster studies.
Coordination with third‑party manufacturers for scale-up, fill–finish and distribution support for vaccine and adjuvant products.
Assistance in preparing regulatory dossiers, engaging with national regulators and pursuing provisional determinations and market authorisations.
Expertise Areas
- Recombinant protein subunit vaccine development
- Adjuvant formulation and characterisation (polysaccharide particles with TLR agonists)
- Clinical trial design and operational management (Phase 1–3)
- Preclinical efficacy and pathogen challenge models
Key Technologies
- Recombinant protein subunit antigens
- Polysaccharide-based adjuvant particles
- TLR/CpG adjuvant combinations
- Inhalation and intranasal vaccine delivery platforms
News & Updates
A groundbreaking vaccine designed to combat Alzheimer’s disease is set to begin human trials in Adelaide, Australia next week. This marks a significant advancement in the fight against dementia. Developed by Vaxine Pty Ltd in collaboration with the Institute for Molecular Medicine, the vaccine aims to stimulate the immune system to produce antibodies that target Alzheimer’s disease.
Dying Patients Fear Pioneering Trial will be forced to shut Down The Daily Telegraph has published an article highlighting a critical issue facing a pioneering cancer vaccine trial. The trial, which offers hope to terminally ill patients, is under threat of being shut down due to decisions made by the government health network.
The COVID-19 vaccine developed by Vaxine has now received a marketing authorisation from the Iranian FDA for children aged 5 years and above. This follows a successful clinical trial where the vaccine was tested in children between 5 and 18 years of age and was shown to be safe and effective in inducing neutralizing antibodies.
Vaxine is actively engaged in developing its own vaccine portfolio, including the Advax™ Adjuvant Platform, a patented delta inulin polysaccharide adjuvant platform.
Vaxine developed the first swine flu pandemic vaccine in 2009, demonstrating its pioneering role in vaccine development.
A groundbreaking vaccine designed to combat Alzheimer’s disease is set to begin human trials in Adelaide, Australia next week. This marks a significant advancement in the fight against dementia. Developed by Vaxine Pty Ltd in collaboration with the Institute for Molecular Medicine, the vaccine aims to stimulate the immune system to produce antibodies that target Alzheimer’s disease.
Dying Patients Fear Pioneering Trial will be forced to shut Down The Daily Telegraph has published an article highlighting a critical issue facing a pioneering cancer vaccine trial. The trial, which offers hope to terminally ill patients, is under threat of being shut down due to decisions made by the government health network.
The COVID-19 vaccine developed by Vaxine has now received a marketing authorisation from the Iranian FDA for children aged 5 years and above. This follows a successful clinical trial where the vaccine was tested in children between 5 and 18 years of age and was shown to be safe and effective in inducing neutralizing antibodies.
Vaxine is actively engaged in developing its own vaccine portfolio, including the Advax™ Adjuvant Platform, a patented delta inulin polysaccharide adjuvant platform.
Vaxine developed the first swine flu pandemic vaccine in 2009, demonstrating its pioneering role in vaccine development.